Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Events

Cardiff Oncology Clinical and Corporate Update Webcast and Conference Call
 September 12, 2022
 4:30pm - 5:30pm EDT

On Monday, September 12, 2022, Cardiff Oncology management will host a webcast and conference call to provide a clinical and corporate update. The event will feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) and updates on other development programs.

Webcast Link:

Here

U.S. Dial-in:

1-877-407-9208

International Dial-in:

1-201-493-6784

Conference ID:

13731618